Latest News and Press Releases
Want to stay updated on the latest news?
-
60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline.
-
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.